Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Echinobase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
Echinobase
ECB-ART-50997
Clin Kidney J 2022 Feb 26;158:1475-1482. doi: 10.1093/ckj/sfac062.
Show Gene links Show Anatomy links

Anaplastic lymphoma kinase inhibitors and their effect on the kidney.

Bonilla M , Jhaveri KD , Izzedine H .


???displayArticle.abstract???
Lung cancer is the leading cause of cancer-related mortality and approximately 5% of non-small-cell lung cancer (NSCLC) patients are positive for anaplastic lymphoma kinase (ALK) gene rearrangement or fusion with echinoderm microtubule-associated protein-like 4. ALK inhibitors are the mainstay treatment for patients with NSCLC harboring a rearrangement of the ALK gene or the ROS1 oncogenes. With the recent publication of pivotal trials leading to the approval of these compounds in different indications, their toxicity profile warrants an update. Several ALK-1 inhibitors are used in clinical practice, including crizotinib, ceritinib and alectinib. According to the package insert and published literature, treatment with several ALK-1 inhibitors appears to be associated with the development of peripheral edema and rare electrolyte disorders, kidney failure, proteinuria and an increased risk for the development and progression of renal cysts. This review introduces the different types of ALK inhibitors, focusing on their detailed kidney-related side effects in clinical practice.

???displayArticle.pubmedLink??? 35892021
???displayArticle.pmcLink??? PMC9308093
???displayArticle.link??? Clin Kidney J




???attribute.lit??? ???displayArticles.show???
References [+] :
Adhikari, Hypophosphatemia in cancer patients. 2021, Pubmed